Hamner_logo_1 line_555-11

First Page		Document Content
Date: 2011-02-25 16:03:24 Pharmacokinetics Drug discovery Pharmaceutical industry Toxicology Physiologically based pharmacokinetic modelling Drug development Food and Drug Administration Pre-clinical development Bioavailability Pharmaceutical sciences Pharmacology Medicine		Hamner_logo_1 line_555-11 Add to Reading List Source URL: www.thehamner.org Download Document from Source Website File Size: 2,16 MB Share Document on Facebook

	t 4 Report An Expert Consortium Review of the EC-commissioned Report “Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects – 2010”* DocID: 1nPCG - View Document
	Source-to-Outcome Modeling Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model Linked to a Dietary Exposure Model: Chlorpyrifos as a Case Study Science Issues Paper for SAP Meeting on Chlorpyrifos Physi DocID: 1fHeU - View Document
	Microsoft PowerPoint - CumulativeRisk2011 DocID: 1b2Wv - View Document
	Beyond Science and Decisions: From Issue Identification to Dose-Response Assessment: Apply AEGL Methodology to Develop Acute Exposure Guideline Levels for Ethylbenzene Grant R., Erraguntla N., Hinz J., Camacho I.A. Provi DocID: 1aDg5 - View Document
	BELLE N E W S L E T T E R Biological Effects of Low Level Exposures DocID: 1atNx - View Document